论文部分内容阅读
PURPOSE:To describe a case of orbital cellulitis arising in a patient treated with an anti-TNFα agent.DESIGN:Single interventional case report.METHODS:A 42-year-old man developed severe unilateral orbital cellulitis while receiving infliximab(Remicade,Centocor)treatment for Ankylosing spondylitis(AS)as part of the open-label phase of a trial conducted at our tertiary referral center.Cultures grew Staphylococcus aureus.RESULTS:Infliximab treatment was stopped and the patient made a full recovery after receiving appropriate antibiotic therapy.Infliximab therapy was resumed after three weeks.CONCLUSIONS:Clinical vigilance is warranted when treating patients with anti-TNFα agents as these are associated with a diverse and growing number of ophthalmic complications.Resolved infection does not preclude the use of such agents.
PURPOSE: To describe a case of orbital cellulitis arising in a patient treated with an anti-TNFα agent. DESIGN: Single interventional case report. METHODS: A 42-year-old man developed severe unilateral orbital cellulitis while receiving infliximab (Remicade, Centocor) treatment for Ankylosing spondylitis (AS) as part of the open-label phase of a trial conducted at our tertiary referral center. Cultures grew Staphylococcus aureus .RESULTS: Infliximab treatment was stopped and the patient made a full recovery after receiving appropriate antibiotic therapy. fliximab therapy was resumed after three weeks. CONCLUSIONS: Clinical vigilance is warranted when treating patients with anti-TNFα agents as these are associated with a diverse and growing number of ophthalmic complications. Resolved infection does not preclude the use of such agents.